PPARG and non-small cell lung carcinoma: Even with overexpression of dominant-negative PPARγ, pioglitazone and rosiglitazone suppressed PGE2 in human non-small cell lung cancer (NSCLC) A549 cells, suggesting a PPARγ-independent effect of TZDs.